FDA Pauses "Radical Transparency" Initiative After Industry Pushback Over Drug Rejection Letters

The U.S. FDA has temporarily paused its controversial policy of publishing Complete Response Letters (CRLs) following a citizen petition filed by an undisclosed pharmaceutical company that raised concerns over the disclosure of confidential commercial information.

Introduced in September 2025 as part of the agency's broader "radical transparency" initiative, the policy aimed to publish CRLs—the letters explaining why a drug application was rejected—in real time. The objective was to provide greater insight into regulatory decision-making and help sponsors, researchers, and investors better understand the FDA's review process.

However, the initiative quickly became a source of debate within the pharmaceutical industry.

According to the U.S. Department of Health and Human Services, the FDA suspended the policy in April and is now reviewing both the publication process and its next steps.

The pause follows a petition submitted by legal firm Covington & Burling on behalf of an unnamed pharmaceutical company. The petition argued that the agency should involve sponsors before publication and ensure that all proprietary and commercially sensitive information is properly redacted. It also cited several published CRLs that allegedly contained confidential material.

The last Complete Response Letter published by the FDA was issued on April 22, concerning AbbVie's investigational botulinum toxin, trenibotulinumtoxinE. Since then, more recent drug rejections—including Sobi's gout therapy in late June—have not been accompanied by publicly released CRLs.

The transparency initiative had already resulted in the publication of nearly 300 Complete Response Letters, including high-profile decisions involving therapies from AbbVie, Ultragenyx, Capricor Therapeutics, Replimune and others. While many stakeholders welcomed the increased visibility into the FDA's decision-making process, some companies argued that public disclosure could reveal strategic or proprietary information and potentially affect ongoing development programs.

Despite the temporary pause, the FDA appears committed to pursuing greater regulatory transparency. The agency has proposed regulatory changes that would formally expand its authority to release CRLs and remove the longstanding assumption that the existence of a marketing application is confidential commercial information. Earlier this year, former FDA Commissioner Marty Makary also urged Congress to amend the Federal Food, Drug and Cosmetic Act to explicitly authorize the publication of Complete Response Letters.

Why this matters

The decision highlights the ongoing challenge of balancing regulatory transparency with the protection of confidential commercial information.

For pharmaceutical companies, investors, and regulatory professionals, the outcome of this review could shape how much insight the industry has into FDA decision-making in the future and influence expectations around regulatory communication, intellectual property and competitive strategy.

As the FDA evaluates its next steps, one question remains at the center of the debate:

Can greater transparency improve trust in the regulatory process without compromising innovation?